Is Syntara (ASX:SNT) In A Good Position To Deliver On Growth Plans?
Nov 28
Have your own idea? Try our Stock Screener
Australian (ASX) Pharma Industry Analysis
UpdatedNov 25, 2025
DataAggregated Company Financials
Companies26
- 7D-2.6%
- 3M5.1%
- 1Y-14.1%
- YTD-0.7%
Over the last 7 days, the Pharma industry has dropped 2.6%, driven by Mayne Pharma Group declining 17%. In contrast, Neuren Pharmaceuticals has gained 8.2%. The industry has fallen 14% in the last year. Earnings are forecast to grow by 26% annually.
Industry Valuation and Performance
Has the Australian Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 28 Nov 2025 | AU$5.5b | AU$1.0b | -AU$199,680,775.00 | 14.3x | -27.4x | 5.5x |
| Sun, 26 Oct 2025 | AU$6.4b | AU$1.0b | -AU$202,211,775.00 | 14.3x | -31.6x | 6.4x |
| Tue, 23 Sep 2025 | AU$5.6b | AU$1.0b | -AU$202,211,775.00 | 15.6x | -27.9x | 5.6x |
| Thu, 21 Aug 2025 | AU$5.1b | AU$1.0b | -AU$210,986,150.00 | 14.4x | -24.3x | 5x |
| Sat, 19 Jul 2025 | AU$4.9b | AU$1.1b | -AU$225,511,927.00 | 14.2x | -21.9x | 4.7x |
| Mon, 16 Jun 2025 | AU$4.3b | AU$1.1b | -AU$225,511,927.00 | 12.9x | -19.2x | 4.1x |
| Wed, 14 May 2025 | AU$4.7b | AU$1.0b | -AU$238,266,485.00 | 17.4x | -19.7x | 4.5x |
| Fri, 11 Apr 2025 | AU$3.9b | AU$1.0b | -AU$238,266,485.00 | 17.5x | -16.3x | 3.7x |
| Sun, 09 Mar 2025 | AU$4.8b | AU$1.1b | -AU$289,508,485.00 | 18.5x | -16.6x | 4.5x |
| Tue, 04 Feb 2025 | AU$5.2b | AU$1.0b | -AU$378,981,112.00 | 11.8x | -13.8x | 5.1x |
| Thu, 02 Jan 2025 | AU$5.3b | AU$1.0b | -AU$378,981,112.00 | 12.8x | -14x | 5.2x |
| Sat, 30 Nov 2024 | AU$6.0b | AU$1.0b | -AU$378,981,112.00 | 12.8x | -15.9x | 5.9x |
| Mon, 28 Oct 2024 | AU$6.2b | AU$1.0b | -AU$377,703,112.00 | 13.3x | -16.3x | 6.1x |
| Wed, 25 Sep 2024 | AU$6.8b | AU$1.0b | -AU$370,332,028.00 | 13.2x | -18.4x | 6.7x |
| Fri, 23 Aug 2024 | AU$6.3b | AU$995.3m | -AU$387,920,108.00 | 10.1x | -16.3x | 6.4x |
| Sun, 21 Jul 2024 | AU$6.9b | AU$995.3m | -AU$387,920,108.00 | 11.7x | -17.8x | 6.9x |
| Tue, 18 Jun 2024 | AU$6.5b | AU$1.2b | -AU$379,234,217.00 | 14.7x | -17x | 5.3x |
| Thu, 16 May 2024 | AU$6.1b | AU$1.2b | -AU$374,923,684.00 | 13.6x | -16.3x | 5x |
| Sat, 13 Apr 2024 | AU$5.8b | AU$1.2b | -AU$374,923,684.00 | 14.5x | -15.5x | 4.8x |
| Mon, 11 Mar 2024 | AU$5.5b | AU$1.2b | -AU$380,850,666.00 | 14x | -14.5x | 4.5x |
| Wed, 07 Feb 2024 | AU$5.6b | AU$892.7m | -AU$536,464,511.00 | 20.8x | -10.4x | 6.2x |
| Fri, 05 Jan 2024 | AU$5.9b | AU$896.3m | -AU$589,604,392.00 | 21.3x | -9.9x | 6.5x |
| Sun, 03 Dec 2023 | AU$4.4b | AU$896.3m | -AU$589,604,392.00 | 18.1x | -7.4x | 4.9x |
| Tue, 31 Oct 2023 | AU$3.4b | AU$900.3m | -AU$587,952,018.00 | 18x | -5.8x | 3.8x |
| Thu, 28 Sep 2023 | AU$3.5b | AU$900.3m | -AU$587,952,018.00 | 19.4x | -6x | 3.9x |
| Sat, 26 Aug 2023 | AU$4.1b | AU$1.0b | -AU$640,926,076.00 | 15.4x | -6.4x | 4x |
| Mon, 24 Jul 2023 | AU$4.5b | AU$999.0m | -AU$624,794,303.00 | 22.8x | -7.1x | 4.5x |
| Wed, 21 Jun 2023 | AU$4.0b | AU$999.0m | -AU$624,794,303.00 | 21.3x | -6.4x | 4x |
| Fri, 19 May 2023 | AU$4.2b | AU$993.2m | -AU$640,306,659.00 | 18.2x | -6.5x | 4.2x |
| Sun, 16 Apr 2023 | AU$4.1b | AU$993.2m | -AU$641,969,868.00 | 19.4x | -6.4x | 4.1x |
| Tue, 14 Mar 2023 | AU$3.7b | AU$995.9m | -AU$648,651,745.00 | 20.4x | -5.7x | 3.7x |
| Thu, 09 Feb 2023 | AU$3.7b | AU$951.8m | -AU$584,038,383.00 | 17.7x | -6.3x | 3.9x |
| Sat, 07 Jan 2023 | AU$4.1b | AU$948.3m | -AU$544,428,006.00 | 13.1x | -7.5x | 4.3x |
| Mon, 05 Dec 2022 | AU$4.1b | AU$948.3m | -AU$544,428,005.00 | 13.2x | -7.5x | 4.3x |
Price to Earnings Ratio
-7.5x
Current Industry PE
- Investors are relatively neutral on the Australian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 5.0x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that companies overall are more efficiently conducting business since losses are shrinking while sales have been flat.
Industry Trends
Which industries have driven the changes within the Australian Healthcare industry?
| AU Market | 0.83% | |
| Healthcare | 3.90% | |
| Pharma | -2.60% | |
| Pharma | -2.60% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| NEU Neuren Pharmaceuticals | AU$19.64 | 8.2% +AU$188.5m | 57.5% | PE16.7x | |
| RCE Recce Pharmaceuticals | AU$0.49 | 15.3% +AU$18.8m | 11.4% | PS18.9x | |
| CU6 Clarity Pharmaceuticals | AU$3.61 | 0.8% +AU$11.2m | -43.7% | PS141.9x | |
| SPL Starpharma Holdings | AU$0.41 | 5.2% +AU$8.4m | 252.2% | PS29x | |
| AVE Avecho Biotechnology | AU$0.009 | 28.6% +AU$7.3m | 125.0% | PS23.9x |